fevipiprant fevipiprant fevipiprant (inn; code name qaw039) is a drug being developed by novartis which acts as a selective, orally available antagonist of the prostaglandin d2 receptor 2 (dp2 or crth2). fevipiprantclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status investigational pharmacokinetic databioavailabilityunaffected by foodmetabolismhepatic glucuronidationelimination half-life~20 hoursexcretionrenal (≤30%)identifiers iupac name acetic acid cas number872365-14-5pubchem cid23582412chemspider23582412unii2pex5n7dq4keggd10631echa infocard100.243.911 chemical and physical dataformulac19h17f3n2o4smolar mass426.41 g·mol−13d model (jsmol)interactive image smiles cc1=c(c2=c(n1cc3=c(c=c(c=c3)s(=o)(=o)c)c(f)(f)f)n=cc=c2)cc(=o)o inchi inchi=1s/c19h17f3n2o4s/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8h,9-10h2,1-2h3,(h,25,26)key:gfppxzdrvcsvnr-uhfffaoysa-n as of 2016, it is in phase iii clinical trials for the treatment of asthma. on monday, december 16, 2019, switzerland-based novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. the firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.